Microscopic globular bodies (MGBs) are brilliantly and homogenously eosinophilic spherical inclusions, 1-10 μm in diameter. They are mainly distributed in the cerebral neocortex and hippocampus in normal individuals ranged in age from first to tenth decade. Ultrastructurally, MGBs are composed of electron-dense granular material and are located in dendrites. However, immunohistochemical profile of MGBs is uncertain. Therefore, we immunohistochemically examined the hippocampus from five control subjects ranged from 25 to 76 years. The marginal portion of MGBs was positive for lysosomal proteases (cathepsins B, D and L), and markers of dendrite (MAP2) and dendritic spine (drebrin). In some cases, MGBs were entirely immunostained with anti-cathepsin D. Among the cathepsins, MGBs were most frequently immunolabeled with anticathepsin D. They were negative for ubiquitin, ubiquitin-proteasome system (p62, NUB1 and EDD1), autophagosome (LC3), cytoskeletal proteins (neurofilament, actin, tubulin and cytokeratin), tau, α-synuclein and TDP-43. These findings suggest that MGBs are sequestered by lysosome-protease system, but not by ubiquitin-proteasome system or autophagosome.
Microscopic globular bodies (MGBs) were first described in the normal human brain by Hara (11, 12) . MGBs are brilliantly and homogenously eosinophilic spherical inclusions, 1-10 μm in diameter. Ultrastructurally, they are composed of electron-dense granular material surrounded by single unit membrane and are located in dendrites (2, 12, 20) . Several investigators have referred to these structures as eosinophilic globular body (11) , granular osmiophilic body (20) , dense microsphere (1, 2, 9) and spheron (3, 4) . Although MGBs are distributed widely in the gray matter of the central nervous system, they are most frequent and numerous in the frontal and temporal neocortex and hippocampus (3) . They are found in the human subjects with and without neurological diseases, ranging in age from 1 to 99 years (3, 12) . Such structures are also seen in the cerebral cortex of monkeys, dogs, cows, pigs, raccoons, deer, goats, sheep, horses and bears (3, 8) . Previous histochemical studies have shown that MGBs consist of a proteinaceous component, but without a significant amount of carbohydrate or neutral glycoprotein (2, 8, 9, 12) . Furuoka et al. (8) reported that MGBs in the horse brain is not ubiquitinated. However, immunohistochemical profile of MGBs has not been investigated in detail. Therefore, we immunohistochemically examined the hippocampus from normal human subjects.
MATERIALS AND METHODS

Subjects.
We examined five neurologically normal individuals (25-year-old man, 35-year-old man, 58-year-old man, 68-year-old man and 76-year-old man). For routine histological examination, the brain ubiquitin (1B3; MBL, Nagoya, Japan; 1 : 2,000), anti-p62 (BD Biosciences, Franklin Lakes, NJ, USA; 1 : 100), anti-NUB1 (Y-14; SANTA CRUZ BIOTECHNOLOGY, Santa Cruz, CA, USA; 1 : 50), anti-EDD1 (BETHYL, Montogomery, TX, USA; 1 : 100), anti-neurofilament (70 kD and 200 kD) (2F11; DAKO; 1 : 200), anti-vimentin (V9; DAKO; 1 : 50), anti-cytokeratin (subfamilies A and B) (AE1/ AE3; DAKO; 1 : 50), anti-glial fibrillary acidic protein (GFAP) (DAKO; 1 : 800), anti-actin (20-33; SIGMA, St. Louis, MO, USA; 1 : 200), anti-tubulin (TU-20; CHEMICON, Temecula, CA, USA; 1 : 500), anti-microtubule-associated protein 2 (MAP2) (HM-2; SIGMA; 1 : 100), anti-phosphorylated α-synuclein (#64; WAKO, Osaka, Japan; 1 : 5,000), anti-phosphorylated tau (AT8; Innogenetics, Ghent, Belgium; 1 : 1,000), anti-β amyloid (IBL, Fujioka, Japan; 1 : 100), anti-TDP-43 (10782-1-AP; ProteinTec Group, Inc., Chicago, IL, USA; 1 : 5,000), anti-cystatin C (A0541; DAKO; 1 : 2,000), anti-β-coatomer protein (β-COP) (M3A5; SIGMA; 1 : 100), anti-cytochrome of each subject was fixed with 10% buffered formalin for 3 weeks and then embedded in paraffin. Four-micrometer-thick sections were cut and stained with hematoxylin and eosin (HE) and by the Klüver-Barrera method. For cathepsin D immunohistochemistry, we examined twenty-five subjects without neurodegenerative disorders, ranged in age from 1 to 91 years (Table 1 ). This study was approved by the Institutional Ethics Committee of Hirosaki University Graduate School of Medicine.
Immunohistochemistry. Four-micrometer-thick, paraffin-embedded sections were cut from the temporal lobe at the level of the lateral geniculate body. The sections were subjected to immunohistochemical investigations using the avidin-biotin-peroxidase complex (ABC) method with a Vectastain ABC kit (Vector, Burlingame, CA, USA). In each case, the sections were immunostained with the following primary antibodies: polyclonal anti-ubiquitin (DAKO, Glostrup, Denmark; 1 : 1,000), monoclonal anti- (Fig. 1b, c) . The other type (type 2) was entirely immunostained with anti-cathepsin D (Fig. 1d) .
On the other hand, marginal portion of MGBs were positive for cathepsin B, cathepsin L, MAP2, drebrin, IP 3 R and Tom20 (Fig. 1e-j) . However, they were not immunolabeled with monoclonal and polyclonal anti-ubiquitin antibodies. They were also negative for proteins implicated in the ubiquitin-proteasome system (p62, NUB1 and EDD1), cathepsins A and S, autophagosome (LC3), early endosome (Rab5), cytoskeletal proteins (neurofilament, vimentin, cytokeratin, GFAP, actin and tubulin), structural elements of abnormal inclusions in neurodegenerative disorders (phosphorylated α-synuclein, phosphorylated tau, β-amyloid, TDP-43 and FUS), a marker of Golgi-endoplasmic reticulum complex (cystatin C and β-COP), a marker of endoplasmic reticulum (ryanodine receptor and TxNDC4), a marker of mitochondria (COX IV), and a marker of presynapse (SNAP25). Morphometry. In all cases, sections were stained with HE. Digital images of the hippocampus and parahippocampal gyrus were captured by a virtual slide system (VS110-L100; Olympus, Tokyo, Japan) as reported previously (17) . MGBs were observed under a 40× objective lens. After removing the cover glass from the slides in xylene, the specimens were decolorized in alcohol, pretreated with heat retrieval using an autoclave for 10 min in 10 mM citrate buffer (pH 6.0), and immunostained with the above antibodies and visualization. The sections were counterstained with hematoxylin. Digital images of the hippocampus and parahippocampal gyrus were captured by the virtual slide system again. The immunoreactivity of MGBs was evaluated under a 40× objective lens. The number of MGBs was counted in the unilateral hippocampus and parahippocampal gyrus in each section, since the hippocampus is the predilection site for MGBs and the size of MGBs in the hippocampus is larger than that in the neocortex (3).
RESULTS
MGBs were found in the hippocampus in all five cases on HE-stained sections (Fig. 1a) . Immunohistochemically, MGBs were labeled with antibodies against cathepsins B, D and L (Fig. 1b-f ). They were also immunolabeled with markers of dendrite (MAP2), dendritic spine (drebrin), endoplasmic reticulum (IP 3 R) and mitochondria (Tom20) (Fig. 1g-j) .
neuronal cell death. Felbor et al. (7) reported that cathepsin B/cathepsin L double knockout mice showed brain atrophy, neuronal loss and lysosomal inclusion bodies in large cortical neurons, suggesting that cathepsins B and L have a role in maintenance of the brain. Considering that MGBs are immunopositive for cathepsins B, D and L, they are degraded, at least in part, by the lysosome-protease system. This is supported by the finding that MGBs are not ubiquitinated and are negative for proteins implicated in the ubiquitin-proteasome system (p62, NUB1 and EDD1). They were also negative for a anti-cathepsin D. The association of neurodegeneration with the endosome-lysosome protease system has been reported in various neurological disorders (5, 6, 10, 13-15, 18, 19) . Cathepsin B immunoreactivity is increased in neurofibrillary tangle-containing neurons and dystrophic neurites of senile plaques in Alzheimer's disease (14) as well as in motor neurons in amyotrophic lateral sclerosis (15) . Immunoreactivity of cathepsins B and D is increased in the degenerative regions in the early stage of Alzheimer's disease (6) . These findings suggest that cathepsins B and D are associated with 
marker of autophagosome (LC3).
We further demonstrated that MGBs are also immunolabeled with markers of dendrite (MAP2) and dendritic spine (drebrin). This is consistent with previous ultrastructural studies that MGBs are located in the dendrite (2, 12, 20) . The marginal portion of MGBs was also positive for markers of the endoplasmic reticulum (IP 3 R) and mitochondria (Tom20). This is explained by the facts that the normal dendrites contain a few mitochondria and endoplasmic reticulum and that MGBs are surrounded by the cytoplasm of the dendrites (8, 12 ). However, the major component of MGBs is still uncertain. In the present study, MGBs were negative for proteins implicated in the cytoskeletal proteins (neurofilament, vimentin, cytokeratin, GFAP, actin and tubulin) and structural elements of abnormal inclusions in neurodegenerative disorders (phosphorylated α-synuclein, phosphorylated tau, β-amyloid, TDP-43 and FUS). It is unlikely that MGBs are composed of cytoskeletal proteins. Further studies are necessary to elucidate the constituent proteins of MGBs in the human brain.
Previous studies have shown that MGBs are not seen in newborns but are regularly present by the age of one year (3). They are found in the brain of normal individuals ranged in age from 1 to 99 years (3, 12) . The number of MGBs in the temporal neocortex is stable across age groups (3), whereas the number of MGBs in the whole hemisphere at the level of mammillary body is highest in the fourth decade (12) . Thus, the occurrence of MGBs does not simply reflect aging phenomenon. Moreover, the density of MGBs in the temporal neocortex is significantly decreased in Alzheimer's disease compared to age-matched normal controls (3). Immunoreactivity of cathepsins B and D is increased in the degenerative regions of Alzheimer's disease (6, 14) . In addition, the levels of cathepsin B in plasma and cathepsin D in cerebrospinal fluid are elevated in patients with Alzheimer's disease (21, 23) . It is possible to consider that the degradation of MGBs is accelerated in Alzheimer's disease.
In conclusion, MGBs are dendritic in origin and are sequestered by lysosome-protease system, but not by ubiquitin-proteasome system or autophagosome.
